FDA
-
-
-
-
-
-
-
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
-
-
-
-
-
-
-
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
-
-
-
-
-
-
-
Propanc Biopharma Provides Shareholder Update
-
-
-
-
-
-
-
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
-
-
-
-
-
-
-
Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients
-
-
-
-
-
-
-
Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer
-
-
-
-
-
-
-
Propanc Biopharma’s CEO Believes Proenzyme Therapy May Become the Healthcare Solution of Choice for Treating Cancerous Solid Tumors
-
324,252 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

